Day: March 22, 2023

TORONTO, March 22, 2023 (GLOBE NEWSWIRE) —Reported quarterly diluted earnings per share of $0.26 Positive mutual fund net sales of $221 million for the quarter Increased quarterly dividend to $0.11 per shareAGF Management Limited (AGF or the Company) (TSX: AGF.B) today announced financial results for the first quarter ended February 28, 2023. AGF reported total assets under management and fee-earning assets1 of $41.9 billion compared to $41.8 billion as at November 30, 2022 and $42.0 billion as at February 28, 2022. Year-over-year, the slight AUM decline was driven by market volatility, offset by positive net sales. “During a time of market uncertainty, we remain focused on providing our clients with consistency when it comes to our performance, our investment approach and our client interactions,” said Kevin McCreadie, Chief...

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — Stronghold Digital Mining, Inc. (NASDAQ: SDIG) (“Stronghold”, or the “Company”) provided the following updates regarding its operations and financial performance: Fourth Quarter 2022 Financial Performance Stronghold generated an estimated $23 million of revenue, an estimated $48 million of net loss, and an estimated $5 million of adjusted EBITDA (see reconciliation of non-GAAP financial measures) during the fourth quarter of 2022. Revenue comprised an estimated $14 million from the sale of energy, an estimated $8 million from cryptocurrency mining, and an estimated $1 million from capacity sales during the quarter. The period featured two extremes: record high PJM power prices in December and record low Bitcoin hash price in November. The Company believes that Stronghold’s vertically...

Achieves Third Consecutive Quarter of Year-Over-Year Revenue Growth Reports Strong Execution and Projects Turning Cash Flow Positive in 2023 Zero-Waste Inspired® Mission Continues to Resonate with Environmentally Conscious Consumers and Retail Distribution Partners Resulting in Growing Product Demand  Conference Call to Be Held Today at 11:00 am ET. BELVIDERE, N.J., March 22, 2023 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today provided a business update and reported financial results for the three month and full year periods ended December 31, 2022. Mr. Jim Kras, Chief Executive Officer of Edible Garden, commented, “We are pleased to report that for...

2022 CLINICAL AND REGULATORY HIGHLIGHTSAwarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2 ARTEMIS trial of MT-401 in post-transplant acute myeloid leukemia (AML) Investigational New Drug (IND) application cleared by FDA for multicenter Phase 1 trial of MT-601 for the treatment of metastatic pancreatic cancer in combination with front-line chemotherapyReceived FDA Orphan Drug Designation for MT-601 for the treatment of pancreatic cancerIND for MT-601 for the treatment of non-Hodgkin lymphoma cleared by FDA, focused on patients who have failed or are ineligible for CAR-T therapy2022 CORPORATE AND FINANCIAL HIGHLIGHTSEntered into a services agreement with Wilson Wolf Manufacturing Corporation, which included an $8.0 million upfront cash payment from Wilson Wolf Entered into a common stock purchase...

~ Q4 Net Sales increased 9.7%; Q4 Comparable Store Sales increased 3.0% ~ ~ Q4 Earnings per Share increased 19.7% to $0.85 ~ ~ Q4 Adjusted Earnings per Share increased 21.7% to $0.84 ~ ~ Initiates Fiscal 2023 Guidance ~ HARRISBURG, Pa., March 22, 2023 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today reported financial results for the fourth quarter and full-year fiscal 2022. Fourth Quarter Summary:     Total net sales increased 9.7% to $549.8 million.   Comparable store sales increased 3.0% from the prior year decrease of 10.5%. The Company opened 5 new stores, ending the quarter with 468 stores in 29 states, a year-over-year increase in store count of 8.6%. Operating income increased 17.8% to $67.7 million. Adjusted operating income(1) increased 16.5% to $66.8 million and adjusted...

Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic          Extended leadership in RNA editing and advanced WVE-006 for AATD – first-in-class RNA editing candidate transitioning to clinical development in 2023 Initiating Part B of WVE-N531 study in exon 53-amenable DMD to assess dystrophin after 24 and 48 weeks of biweekly dosing Strategic collaboration with GSK underway, expected to add multiple first-in-class discovery programs to Wave pipeline, including RNA editing and RNAi programs, as well as potential for up to $3.3 billion in milestone payments Well-capitalized with cash runway into 2025 to deliver on multiple catalysts Wave to host investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., March...

Record Annual Cash Flow & Reserve Value Increase NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES ORDISSEMINATION IN UNITED STATES CALGARY, Alberta, March 22, 2023 (GLOBE NEWSWIRE) — Pieridae Energy Limited (“Pieridae” or the “Company”) (PEA.TO) announces the release of its fourth quarter and full year 2022 financial and operating results and year end 2022 reserves. Pieridae generated Net Operating Income (“NOI”)1 of $201 million and made term debt principal repayments totalling $48 million during 2022. In addition, the Company filed its Annual Information Form (“AIF”) for the year ended December 31, 2022 containing Pieridae’s 2022 independent oil and natural reserves evaluation as required under National Instrument 51-101 Standards of Disclosure of Oil and Gas Activities (“NI51-101”). Pieridae’s...

Major progress in development of vilobelimabPhase III study in PG announced following detailed feedback and recommendations from the U.S. Food and Drug Administration (FDA); clinical trial protocol submitted; first patient expected around mid-2023 Fast Track and Orphan Drug designations granted for treatment of pyoderma gangrenosum (PG) in the United States and Orphan Drug designation granted in Europe Encouraging results from Phase III study in critically ill COVID-19 patients published in The Lancet Respiratory Medicine Emergency Use Authorization (EUA) application for treatment of critically ill, invasively mechanically ventilated COVID-19 patients submitted to the FDA; review ongoingFirst-in-human clinical trial with oral C5aR inhibitor INF904 initiated in November 2022; first data expected in H2 2023 Amendment of co-development...